Physician profile
David Rayhan
NPI 1275857898
$9,120.30
in general payments reported to CMS, 2019-2025
15 companies · $574 in 2025
The $574 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $5.13 · 2021: $15.36 · 2022: $7,801 · 2023: $125 · 2024: $293 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $7,801.09 | 2022 | |
| Galderma Laboratories, L.P. | $448.79 | 2019-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.94 | 2024-2025 | Jardiance |
| Amgen INC. | $171.53 | 2024 | Otezla |
| Alexion Pharmaceuticals, INC. | $130.51 | 2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Lokelma |
| Apellis Pharmaceuticals, INC. | $124.26 | 2025 | Empaveli |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Pfizer INC. | $33.18 | 2019-2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rayhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.